Cisplatin and Fluorouracil Induction Chemotherapy With or Without Docetaxel in Locoregionally Advanced Nasopharyngeal Carcinoma

Cisplatin and Fluorouracil Induction Chemotherapy With or Without Docetaxel in Locoregionally Advanced Nasopharyngeal Carcinoma

In this study, we aim to compare the progression-free survival (PFS) rates and side effects of induction chemotherapy based on docetaxel, cisplatin and fluorouracil (TPF) versus cisplatin and fluorouracil (PF) in patients with locoregionally-advanced nasopharyngeal carcinoma who received subsequent...

Full description

Bibliographic Details
Main Authors:	Ting Jin, Wei-feng Qin, Feng Jiang, Qi-feng Jin, Qi-chun Wei, Yong-shi Jia, Xiao-nan Sun, Wen-feng Li, Xiao-zhong Chen
Format:	Article
Language:	English
Published:	Elsevier 2019-04-01
Series:	Translational Oncology
Online Access:	http://www.sciencedirect.com/science/article/pii/S1936523318305199

Similar Items

Real-World Cost-Effectiveness Analysis of Gemcitabine and Cisplatin Compared to Docetaxel and Cisplatin Plus Fluorouracil Induction Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma
by: Jiangping Yang, et al.
Published: (2020-12-01)

Long-term results of locoregionally advanced nasopharyngeal carcinoma treated with cisplatin and 5-fluorouracil induction chemotherapy with or without docetaxel in young and middle aged adults
by: Yuming Zheng, et al.
Published: (2025-03-01)

Liposomal paclitaxel versus docetaxel in induction chemotherapy using Taxanes, cisplatin and 5-fluorouracil for locally advanced nasopharyngeal carcinoma
by: Sai-Lan Liu, et al.
Published: (2018-12-01)

Effect of induction chemotherapy with cisplatin, fluorouracil, with or without taxane on locoregionally advanced nasopharyngeal carcinoma: a retrospective, propensity score-matched analysis
by: Guo-Ying Liu, et al.
Published: (2018-05-01)

Induction chemotherapy regimen of docetaxel plus cisplatin versus docetaxel, cisplatin plus fluorouracil followed by concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: Preliminary results of an open-label, noninferiority, multicentre, randomised, controlled phase 3 trial
by: Yan Wang, et al.
Published: (2022-11-01)

Docetaxel and cisplatin induction chemotherapy with or without fluorouracil in locoregionally advanced head and neck squamous cell carcinoma: A real-world data study
by: Matheus Yung Perin, et al.
Published: (2025-05-01)

Comparison of Gemcitabine Plus Cisplatin vs. Docetaxel Plus Fluorouracil Plus Cisplatin Palliative Chemotherapy for Metastatic Nasopharyngeal Carcinoma
by: Xue-Song Sun, et al.
Published: (2020-08-01)

Endostar Combined with Gemcitabine and Cisplatin Chemotherapy for Patients with Metastatic Nasopharyngeal Carcinoma: an Update
by: Ting Jin, et al.
Published: (2018-04-01)

Induction gemcitabine and cisplatin in locoregionally advanced nasopharyngeal carcinoma
by: Yuan Zhang, et al.
Published: (2019-06-01)

Concurrent Chemoradiotherapy With or Without Induction Chemotherapy for Patients with Stage II Nasopharyngeal Carcinoma: An Update
by: Ting Jin, et al.
Published: (2020-01-01)

Induction chemotherapy for locoregionally advanced nasopharyngeal carcinoma
by: Wen-Fei Li, et al.
Published: (2016-11-01)

Assessment of neoadjuvant chemotherapy with docetaxel, cisplatin, and fluorouracil in patients with oral cavity cancer
by: Jin Ye Fu, et al.
Published: (2023-02-01)

The Acute Toxicities and Efficacy of Concurrent Chemotherapy With Docetaxel Plus Cisplatin, or Docetaxel, or Cisplatin and Helical Tomotherapy in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma: A Randomized Single-Center Phase II Trial
by: Yanrong Luo MD, et al.
Published: (2022-06-01)

Concurrent chemoradiotherapy with weekly docetaxel versus cisplatin in the treatment of locoregionally advanced nasopharyngeal carcinoma: a propensity score-matched analysis
by: Jun-Fang Liao, et al.
Published: (2019-06-01)

A comparison of neoadjuvant chemotherapy with gemcitabine versus docetaxel plus cisplatin in locoregionally advanced nasopharyngeal carcinoma: a propensity score matching analysis
by: Liu T, et al.
Published: (2018-11-01)

Individualised cumulative cisplatin dose for locoregionally advanced nasopharyngeal carcinoma patients based on induction chemotherapy response and tumour volume
by: Jie-Yi Lin, et al.
Published: (2024-10-01)

Induction chemotherapy followed by radiotherapy concurrent chemoradiotherapy in the treatment of different risk locoregionally advanced nasopharyngeal carcinoma
by: Li-Ting Liu, et al.
Published: (2020-06-01)

Comparison of the pre-treatment functional MRI metrics’ efficacy in predicting Locoregionally advanced nasopharyngeal carcinoma response to induction chemotherapy
by: Da-wei Zhao, et al.
Published: (2021-11-01)

Induction chemotherapy with dose-modified docetaxel, cisplatin, and 5-fluorouracil in Asian patients with borderline resectable or unresectable head and neck cancer
by: Hung-Ming Wang, et al.
Published: (2017-03-01)

Optimizing induction chemotherapy regimens for radiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma
by: Ying Li, et al.
Published: (2023-04-01)

In search for optimal induction chemotherapy for advanced nasopharyngeal cancer: Standard dosing of Docetaxel, Platinum, and 5-Fluorouracil (TPF) followed by chemoradiation.
by: Michelle Jun, et al.
Published: (2023-01-01)

Efficacy of docetaxel, cisplatin, and 5-fluorouracil as an induction chemotherapy in oral squamous cell carcinoma in a tertiary hospital in Saudi Arabia
by: Mohammad Alessa, et al.
Published: (2024-01-01)

Novel Plasma Proteomic Biomarkers for Early Identification of Induction Chemotherapy Beneficiaries in Locoregionally Advanced Nasopharyngeal Carcinoma
by: Shan-Qiang Zhang, et al.
Published: (2022-06-01)

Efficacy of adjuvant chemotherapy/maintenance chemotherapy after induction chemotherapy and concurrent chemoradiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma: Experiences of two centers
by: Hao‐Yun Tao, et al.
Published: (2023-03-01)

Cisplatin-based concurrent chemoradiotherapy improved the survival of locoregionally advanced nasopharyngeal carcinoma after induction chemotherapy by reducing early treatment failure
by: Xing-Li Yang, et al.
Published: (2022-11-01)

Anti-PD1 checkpoint inhibitor with or without chemotherapy for patients with recurrent and metastatic nasopharyngeal carcinoma
by: Ting Jin, et al.
Published: (2021-02-01)

ATR activated by EB virus facilitates chemotherapy resistance to cisplatin or 5-fluorouracil in human nasopharyngeal carcinoma
by: Zhang B, et al.
Published: (2019-01-01)

Individualized number of induction chemotherapy cycles for locoregionally advanced nasopharyngeal carcinoma patients based on early tumor response
by: Yu‐Ting Jiang, et al.
Published: (2023-02-01)

Prognostic effect of residual plasma Epstein–Barr viral DNA after induction chemotherapy for locoregionally advanced nasopharyngeal carcinoma
by: Hua Zheng, et al.
Published: (2023-07-01)

Induction chemotherapy in locoregionally advanced nasopharyngeal carcinoma: A systematic review and meta-analysis
by: Bi-Cheng Wang, et al.
Published: (2022-07-01)

Modified DCF (Docetaxel, Cisplatin and 5-fluorouracil) chemotherapy is effective for the treatment of advanced rectal squamous cell carcinoma
by: Laure Hervé, et al.
Published: (2022-11-01)

Locoregional Extension Patterns of Nasopharyngeal Carcinoma Detected by FDG PET/MR
by: Caineng Cao, et al.
Published: (2021-12-01)

Chronomodulated chemotherapy for locoregionally advanced nasopharyngeal carcinoma: A phase II randomized controlled trial
by: Xiaoxiao Chen, et al.
Published: (2024-03-01)

Stage-specific concurrent chemoradiotherapy with or without induction chemotherapy for locoregionally advanced nasopharyngeal carcinoma: a retrospective, population-based study
by: Xia WX, et al.
Published: (2019-11-01)

The immune modulation effects of gemcitabine plus cisplatin induction chemotherapy in nasopharyngeal carcinoma
by: Xiao‐Min Li, et al.
Published: (2022-09-01)

Preoperative chemotherapy with docetaxel, cisplatin, and 5-fluorouracil for locally advanced esophageal carcinosarcoma: a case report and review of the literature
by: Tomoko Yoshimoto, et al.
Published: (2018-02-01)

Dramatic response to modified docetaxel, cisplatin, and fluorouracil chemotherapy after immunotherapy in a patient with refractory metastatic anal cancer
by: Faisal Shahjehan, et al.
Published: (2019-09-01)

The Clinical Outcomes and Toxicities of Induction Chemotherapy Followed by Concurrent Chemoradiotherapy Plus Adjuvant Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma
by: Rui Zou, et al.
Published: (2021-02-01)

Ganoderma spore lipid ameliorates docetaxel, cisplatin, and 5-fluorouracil chemotherapy-induced damage to bone marrow mesenchymal stem cells and hematopoiesis
by: Haohui Lin, et al.
Published: (2024-04-01)

The Most Efficacious Induction Chemotherapy Regimen for Locoregionally Advanced Nasopharyngeal Carcinoma: A Network Meta-Analysis
by: Horace Cheuk-Wai Choi, et al.
Published: (2021-02-01)